Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Paroxetine (low-dose)
Treatment for Menopause
Typical Dosage: 7.5mg orally once daily
Effectiveness
70%
Safety Score
60%
Clinical Trials
4
Participants
7.5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
7.5mg orally once daily
Time to Effect
2-4 weeks
Treatment Duration
Long-term, as needed
Evidence Quality
HIGHNumber Needed to Treat (NNT)
7(Treat 7 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
1000(Treat 1000 patients to see 1 additional serious adverse event)
Confidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$200
Monitoring:$100
Side Effect Mgmt:$50
Total Annual:$350
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$30,000/QALY
QALYs Gained
0.15
Outcome-Based Costs
Cost per Responder
$636.36
Cost per Remission
$1,400
Paroxetine (low-dose) Outcomes
for Menopause
Efficacy Outcomes
Overall Effectiveness
+70%
Response Rate
+55%
Remission Rate
+25%
Common Side Effects
Nausea
+15%
Insomnia/Somnolence
+12%
Fatigue
+8%
Headache
+10%
Dry mouth
+7%
Sexual dysfunction
+7%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
4 completed trials for Paroxetine (low-dose) in Menopause
Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women
NCT01829919COMPLETEDPHASE1
24 participants
INTERVENTIONAL
Baltimore, United States
Started: Jul 1, 2011
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
NCT01361308COMPLETEDPHASE3
614 participants
INTERVENTIONAL
Mobile, United States +73 more
Started: May 1, 2011
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
NCT01101841COMPLETEDPHASE3
570 participants
INTERVENTIONAL
Montgomery, United States +31 more
Started: Mar 1, 2010
Eight-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms Associated With Menopause
NCT00786188COMPLETEDPHASE2
102 participants
INTERVENTIONAL
Lake Worth, United States +9 more
Started: Nov 1, 2008